5. Conclusions
dyslipidemia
ELEVATED CHOLESTEROL, DYSLIPIDEMIA
Our study provides robust evidence supporting the modulatory role of PPARG polymorphisms in lipid metabolism in response to omega-3 fatty acid supplementation. The data obtained from this randomized, double-blind, parallel-group clinical trial unequivocally demonstrate that patients with PPARG polymorphisms, who are at low-to-moderate cardiovascular risk and present with elevated cholesterol levels, benefit significantly from the introduction of omega-3 fatty acids into their diet. These benefits are manifested in substantial reductions in LDL-C, total cholesterol, and serum triglycerides over a three-month period.Importantly, the findings highlight the potential for personalized nutrition strategies, suggesting that genetic profiling could be an invaluable tool in optimizing lipid-lowering interventions. Patients carrying PPARG polymorphisms showed greater improvements in lipid profiles, indicating that genetic predispositions should be considered when prescribing omega-3 fatty acid supplementation. This could lead to more tailored and, consequently, more effective approaches to managing dyslipidemia and reducing cardiovascular risk.Future research should aim to expand on these findings by exploring the long-term effects of omega-3 supplementation in genetically diverse populations and elucidating the molecular mechanisms underlying the interaction between PPARG variants and lipid metabolism. Our study lays the groundwork for a new paradigm in personalized medicine, where genetic information guides clinical decisions, leading to improved patient outcomes.